In the treatment of high-risk and extremely high-risk localized prostate cancer，urologists，radiation therapists and oncologists have different opinions. With the development of new systemic therapy drugs and the application of genetic testing，treatment methods are constantly evolving. This article reviews the latest research progress，including radical prostatectomy，lymph node dissection，radiotherapy，and systemic treatment regimens (docetaxel-based therapy，novel endocrinotherapy，immunotherapy，targeted therapy)，to systematically evaluate the long-term survival and tumor control efficacy of different treatment methods，so as to provide clinical reference.

Objective:To investigate the safety and efficacy of low molecular weight heparin (LMWH) bridging program in the perioperative period of mini-percutaneous nephrolithotomy (mPCNL) for long-term antithrombotic patients.Methods:The clinical data of 50 patients who received long-term antithrombotic therapy with mPCNL in Sun Yat-sen Memorial Hospital from January 2013 to December 2017 were retrospectively analyzed. Perioperative anticoagulation plans were drawn up after discussion with an internist. Patients with high thrombosis risk were bridged with LMWH during the perioperative period. Resumed LMWH anticoagulation within 48 hours after surgery. Patients with low or medium thrombosis risk directly discontinued anticoagulation one week before surgery. Preoperative anticoagulation was resumed within 48 hours after removing the nephrostomy tube in all patients. We analyzed the general information before surgery, data during surgery, postoperative hemoglobin changes and stone-free rate (SRF) of all cases. 21 patients were treated with LMWH bridging (bridging group), and 29 patients were directly discontinued with anticoagulant drugs (non-bridging group). There was no statistical difference between the two groups in age [(59.7±7.1) vs. (52.4±10.4)years] , gender [(male/female), 14/7 vs. 19/10], BMI [ (24.3±3.9) kg/m 2 vs. (24.7±5.1) kg/m 2], S. T.O.N.E. score (7.4±1.1 vs. 6.9±1.0), stone surface area [ 314.0(31.4-1 130.4) mm 2 vs. 282.5(64.7-866.0) mm 2], the number of calculi involved in calyces (6/15 vs. 13/16) and stone-related surgical history [ 34% (7/21) vs. 24% (7/29) ]. Results:In the bridging group, 18 patients (86%) performed single-channel mPCNL, 3 patients (14%) underwent dual-channel mPCNL, and the operation time was 80 (35-180) min. In the non-bridging group, 27 patients (93%) underwent single-channel mPCNL, 2 patients (7%) performed dual-channel mPCNL, and the operation time was 80 (30-60) min. The mean changes in hemoglobin in the bridging group and the non-bridging group was 18 (-2 -66) g/L and 14 (-25-64) g/L, respectively ( P = 0.073). The average postoperative hospital stay in the bridging group was (8.6 ± 3.5) days, and the non-bridging group was (7.1 ± 2.3) days ( P= 0.057). Two patients in each group received blood transfusion, and no patients received interventional embolization. The SRF of bridging group and non-bridging group was 81.0% (17/21) vs. 75.9% (22/29) ( P = 0.67) 1 month after the operation. During the perioperative period, no patients had thrombotic complications. Conclusions:When mPCNL was required for long-term antithrombotic treatment patients, the use of LWMH alternatives during the perioperative period did not increase bleeding related complications.

Objective: To evaluate the effect of atropine penalization for treatment of moderate and severe anisometropic amblyopia. Methods: Retrospective cohort study was performed.Eighty moderate and severe anisometropic amblyopia pediatric patients aged 4-7 years old were enrolled from December 2011 to November 2017 in Tianjin Eye Hospital and Beijing Children's Hospital.The subjects were divided into atropine penalization group and patching group according to the treatment, with 25 cases of moderate amblyopia and 15 cases of severe amblyopia in each group.The best corrected visual acuity (BCVA) of amblyopia in atropine penalization group and patching group before treatment, 2 months, 4 months, 6 months and 8 months after treatment were compared.The binocular visual function of each group was compared before and after treatment.The compliance and complications were also recorded.This study adhered to the Declaration of Helsinki, and was approved by the Ethics Committee of Tianjin Eye Hospital (2016-42) and Beijing Children's Hospital (2019-k-33). Results: There were significant differences in BVCA between the two groups before and after treatment in cases with moderate amblyopia (F_group=3.104, P=0.032; F_time=4.342, P=0.013); The BCVA of atropine penalization group was better than that of patching group at 2, 4, 6 and 8 months after treatment, the differences were statistically significant (all at P<0.05). There were significant differences in BCVA between the two groups before and after treatment in cases with severe amblyopia (F_group=3.149, P=0.016; F_time=5.094, P=0.024); The BCVA of atropine penalization group was better than that of patching group at 2, 4, 6 and 8 months after treatment, the differences were statistically significant (all at P<0.05). The effective rates of stereopsis reconstruction in atropine penalization group were significantly higher than those in patching group in both moderate and severe amblyopia cases, and the differences were statistically significant (both at P<0.05). The compliance rate of moderate amblyopia in atropine penalization group was 96% (24/25), which was significantly higher than 76% (19/25) in patching group, the difference was statistically significant (χ²=4.153, P=0.042). The compliance rate of severe amblyopia in atropine penalization group was 100% (15/15), which was also significantly higher than 67% (10/15) in patching group, the difference was statistically significant (χ²=6.000, P=0.014). During the follow-up period, there were 4 cases with photophobia in the atropine penalization group.No adverse reaction was observed in the patching group. Conclusions Compared with patching, atropine penalization is an effective method in treatment of moderate and severe amblyopia, with the advantage in rapid improvement of visual acuity, stereopsis recovery and compliance of treatment.Atropine penalization is worthy for clinical application.

This article collects related literatures which is about the Chinese medicine adjuvant treatment of bladder urothelial carcinoma, and sums up the etiology, pathogenesis and TCM auxiliary treatment methods of this disease. Through the analysis, it is believed that the pathogeny of the disease is mainly concentrated in the aspects of damp, heat, blood stasis and poison. The literature on the adjuvant treatment of bladder urothelial carcinoma mainly focuses on the treatment of syndrome differentiation, postoperative recovery, postoperative perfusion, adjuvant chemotherapy and palliative therapy. The progress of its research is summarized as follows.

Stress Urinary Incontinence (SUI) has a higher incidence in middle-aged and elderly women. At present, for mild and moderate SUI patients, the treatment of kegel practice or combined with TCM ,and acupuncture, acupoint application or pelvic floor muscle exercise show benefit effect. This article summarized the etiology and pathogenesis of SUI, TCM therapy, integrated traditional Chinese and Western Medicine, in recent years, in order to provide reference for the treatment of the disease and the further study.

Objective To evaluate the effectiveness of Lingshao-Zaoren granule in the treatment of female overactive bladder. Methods A total of 60 female OAB patients who met the inclusion criteria were randomly divided into 2 groups, 30 cases in each group. The control group recieved the Tolterodine Tartrate Sustained Release Tablets and the Lingshao-Zaoren granule placebo, and the treatment group used the Tolterodine Tartrate Sustained Release Tablets and the true Lingshao-Zaoren granule treatment. Both groups were treated for 4 weeks. Overactive bladder symptom scale (OABSS) was used to determine the severity of OAB.Results After treatment 14,28 d,OABSS scores of the treatment group(5.3 ± 2.3,1.4 ± 1.2 vs.8.4 ± 2.4,F=137.209),and control group(7.8 ± 1.9,6.8 ± 1.4 vs.8.6 ± 2.6,F=8.927),were significantly lower than the baseline of each group respectively (P<0.01). Besides, OABSS scores of the treatment group after 14 and 28 d were significantly lower than the control group (t=4.668, 15.678, P<0.01). The pain scores (5.9 ± 1.9, 2.7 ± 1.1 vs.9.5 ±2.3,F=108.819)of treatment group at 14 and 28 d were significantly lower than the baseline(P<0.01);and the pain scores of treatment group at 14 and 28 d were significantly lower than the control group (t=6.342, 14.812,P<0.01).The lower abdomen discomfort scores at 14,28 d in treatment group(1.9 ± 1.4,1.1 ± 1.0 vs. 3.3 ±1.1,F=28.762),and control group(2.7 ±1.0,2.4 ±0.8 vs.3.4 ±1.2,F=12.103)were significantly lower than the baseline of each group (P<0.01); and the abdominal discomfort scores of treatment group at 14, 28 d were significantly lower than the control group (t=2.521, 5.041, P<0.05 or P<0.01). Conclusions The Lingshao-Zaoren granule could decrease OABSS score,pain score,abdominal discomfort symptoms,improve clinical symptoms of the female patients with OAB.

ObjectiveTo investigate the effect ofHuayu-Niaoshidecoction on renal injury in the patients with kidney stones after extra corporeal lithotripsy (ESWL). MethodsAccording to the inclusion criteria, 120 patients diagnosed with kidney stones were randomly divided into 2 groups with the random number table method, 60 patients in each group. Both groups were treated with double pulse extracorporeal shock wave lithotripsy (ESWL). Based on the ESWL, the control group was added with levofloxacin mesylate tablets for 3 days with the start of the day of the gravel; and the treatment group was treated withHuayu-Niaoshi decoction for 14 days based on the treatment of control group. The levels of serum endothelial endothelin 1 (ET-1), malondialdehyde (MDA), urinary N-acetyl-β-Dglucosaminidase (NAG) N-acetyl-beta-d Glucosaminidase and urine beta 2 microspheres protein (beta eukaryotic 2-mg) were detected at time of gravel, 2 hours after gravel and 2 weeks after gravel. ResultsAfter 2 weeks treatment, the levels of urinary NAG (7.33 ± 4.39 U/L vs. 9.93 ± 5.10 U/L;Z=2.587,P=0.002), serum MDA (4.63 ± 0.90 nmol/mlvs. 7.29 ± 2.16 nmol/ml;Z=5.520, P=0.001), serum ET-1 (35.06 ± 10.51 pg/mlvs. 46.90 ± 18.74 pg/ml;Z=3.315,P=0.001) and urineβ2-MG (0.14 ± 0.19) mg/Lvs. 0.19 ± 0.19 mg/L;Z=1.759,P=0.079) in the treatment group were significantly lower than those in the control group. Conclusions TheHuayu-Niaoshidecoction can improve renal injury in the patients with
kidney stones after extra corporeal lithotripsy.

Objective To evaluate the clinical curative effect of compoundTufuling tablets in the treatment of chronic prostatitis due to damp heat stagnation.Methods A total of 60 patients with chronic prostatitis due to damp heat stagnation were selected from July 2012 to July 2013 in Urology Outpatient of Urology, Xiyuan Hospital and recruited randomly divided into 2 groups, 30 patients in each group. The treatment group was treated with compound SmilaxTufuling tablets, while the control group was treated with Qianliexin capsule. The National Institutes of Health Chronic Prostatitis Symptom Index (NHI-CPSI), and the TCM symptoms score for chronic prostatitis were used to evaluate the treatment outcome.Results The total efficiency in the treatment group was significant higher than that in the control group (89.3%vs. 64.3%;χ2=4.909,P=0.027). After treatment , the NIH-CPSI total score (6.00 ± 2.36vs. 13.61 ± 2.91;t=10.748, P=0.000), and the subscales of pain or discomfort (2.54 ± 1.14vs. 4.82 ± 1.47;t=6.486,P=0.000), urination (1.61 ± 1.45vs. 4.79 ± 2.75;t=5.413,P=0.000), the quality of life (1.86 ± 1.38vs. 7.00 ± 1.36;t=14.038, P=0.000), TCM symptoms score (8.36 ± 3.03vs. 5.32 ± 2.74;t= 9.015,P=0.000) in the treatment group were decreased than those in the control group.Conclusions CompoundTufuling tablets can significantly decrease the NIH-CPSI scale and the TCM symptoms score in patients with chronic prostatitis due to damp heat stagnation, boosting satisfactory clinical effects.

Objective To evaluate the efficacy ofLingshao-Zaoren particle combined with Tolterodine Tartrate tablet in the treatment of overactive bladder in women.Methods A total of fifty female patients diagnosed with overactive bladder were randomized to receivingLingshao-Zaoren particle combined with Tolterodine Tartrate tablet group(treatment group,n=25) or only Tolterodine Tartrate tablet group(control group, n=25). Both groups were treated for 4 weeks. Changes of scores from the Overactive Bladder Symptom Scale (OBASS) and the Urgent Urination Scale were assessed.Results The scores from the OBASS improved significantly after treatment than those before treatment in both groups(in the treatment group: 3.24±0.61vs.12.16± 1.39,P<0.01; in the control group: 8.81±1.55vs.13.12±1.45,P<0.01) and so did the Urgent Urination Scale (in the treatment group: 1.04±0.72vs. 3.99±0.78,P<0.01; in the control group: 2.61±0.88vs.4.01±0.71,P<0.01) . There were significantly greater improvements in the scores from the OBASS and the Urgent Urination Scale in the treatment group than those in the control group(allP<0.01).ConclusionLingshao-Zaoren particle combined with Tolterodine Tartrate tablet was superior to only Tolterodine Tartrate tablet for the treatment of overactive bladder in women.

Objective To observe the effects of Bupi-Guhuo decoction in treating astringent Ⅰ,Ⅱ degree of female stress urinary incontinence.Methods 70 Women patients with stress urinary incontinence in outpatient of urology of Xiyuan Hospital of CACMS from December 2012 to October 2011 were randomly divided into a treatment group and a control group,with 35 cases in each group.The treatment group was treated with Bupi-Guhuo decoction,twice daily,1package per time; while the patients in the control group were treated with pelvic floor muscle training therapy.Both groups were treated for 4 weeks.Results The score of ICS-Q-SF and the amount of urinary incontinence comparison:2 weeks after treatment [the treatment group was (6.42～0.79) and (8.85～ 1.07) g respectively; the control group was (6.81～0.91) and (9.35～ 1.23) g respectively].Both groups had obvious improvement than before the treatment [the treatment group (7.73 ～ 1.52) and (12.92 ～2.08) g respectively,the control group was (7.71～ 1.48)and (13.28～2.43) g respectively] (P＜0.01).4 weeks after the treatment [treatment group was(2.68～0.91)and(2.62～1.08) g respectively,the control group was (6.25～0.81) and (8.02～ 1.32)g respectively].Compared with the effects of 2 weeks after treatment,the difference was statistically significant (P＜0.01) in the treatment group,while with no significant change (P＞0.05) in the control group.At the 2 weeks,4 weeks treatment,the effects in the treatment group and the control group had statistical difference (P＜0.05 or 0.01).(②)Clinical curative effect comparison:After treatment,the total effective rate was 67.7％ (21/31) in treatment group and 37.0％ (10/27) in the control group,showing significant difference (P=0.000,P＜0.01).Conclusion Bupi-Guhuo decoction had better therapeutic effects than pelvic floor muscle training in the treatment of female Ⅰ,Ⅱ degree of stress urinary incontinence,also with a time-effect relationship.